ASSAY DEVELOPMENT CONSULTING SERVICES FOR NINDS' HEAL PROGRAM.

检测开发 检测开发顾问将提供高级工艺化学专业知识，并通过电话会议和电子邮件向NIH和LDT成员提供项目反馈和指导。工艺化学顾问的职责可能包括但不限于以下职责和任务： · 可能需要顾问评估生物活性测定并推荐策略和实验，以优化和/或验证用于药物化学活动的测定。 · 可能要求检测开发顾问协助建立与检测优化或验证相关的里程碑。 · 可能需要顾问就常用的体内试验（如认知和行为测试）的设计和解释提供指导。 · 作为检测试剂盒开发专家，以识别潜在的开发挑战，并提出在现实时间表内解决这些挑战的策略。 · 与其他顾问，承包商和NIH工作人员合作，提供建议，战略规划和管理计划，以促进铅优化，IND启用和临床研究。 · 作为一种资源，领导开发团队成员的分析要求，并从临床前阶段到初始临床阶段进行小分子化合物的药物开发活动的物流。 · 与其他顾问，承包商和NIH工作人员合作，提供建议，战略规划和管理计划，以促进铅优化，IND启用和临床研究。 · 作为一种资源，领导开发团队成员的分析要求，并从临床前阶段到初始临床阶段进行小分子化合物的药物开发活动的物流。 · 合作设计调查研究，以支持开发化合物。 这项研究是NIH帮助结束长期成瘾（HEAL）计划的一部分，旨在加速科学解决方案，以了解疼痛的基础并加强临床疼痛管理。这是该计划的一部分，该计划为各种疼痛状况建立了新的治疗方案，以改善生活质量并减少阿片类药物依赖。 该计划研究了广泛的疼痛状况，包括慢性重叠疼痛状况，慢性肌肉骨骼疼痛，围手术期疼痛和膝关节骨关节炎。

Assay Development Assay Development consultants will be expected to provide senior-level Process Chemistry expertise and contribute feedback and guidance on projects to the NIH and to LDT members through conference calls and by email. The role of the Process Chemistry consultant may include but is not limited to the following responsibilities and tasks: • Consultants may be required to evaluate bioactivity assays and recommend strategies and experiments to optimize and/or validate the assays for use in a medicinal chemistry campaign. • Assay development consultants may be asked to assist in the establishment of milestones related to assay optimization or validation. • Consultant may be required provide guidance on the design and interpretation of commonly used in vivo assays, such as cognitive and behavioral tests. • Serve as the assay development expert in order to identify potential developmental challenges and suggest strategies to address these challenges on realistic timelines. • In partnership with other consultants, contractors, and the NIH staff, advise, strategically plan, and manage programs to facilitate lead optimization, IND enabling, and clinical studies. • Serve as a resource to lead development team members for assay requirements, and logistics to conduct drug development activities for small molecule compounds from the preclinical stage through to the initial clinical stage. • In partnership with other consultants, contractors, and the NIH staff, advise, strategically plan, and manage programs to facilitate lead optimization, IND enabling, and clinical studies. • Serve as a resource to lead development team members for assay requirements, and logistics to conduct drug development activities for small molecule compounds from the preclinical stage through to the initial clinical stage. • Collaborate on the design of investigative studies in support of development compounds. This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. It’s part of the program that establishes novel treatment options for a variety of pain conditions to improve quality of life and reduce opioid dependency. The program studies a broad range of pain conditions, including chronic overlapping pain conditions, chronic musculoskeletal pain, perioperative pain, and knee osteoarthritis.